Heat Biologics, Inc. (NASDAQ:HTBX) Files An 8-K Results of Operations and Financial ConditionItem 2.02. Results of Operations and Financial Condition.
Heat Biologics, Inc. (the “Company”) filed a preliminary prospectus supplement on March 23, 2017 with the Securities and Exchange Commission that disclosed certain financial information and operating data as of and for the year ended December 31, 2016. While complete and final information is not yet not available, the Company’s management preliminarily estimates that for the year ended December 31, 2016, the Company will report a loss from continuing operations of approximately $13.0 million. Management also estimates cash of approximately $7.8 million at December 31, 2016.
These estimates are preliminary and may change. The Company’s auditors and the Company have not completed their normal annual review procedures for the year ended December 31, 2016, and there can be no assurance that the final results for this year will not differ from these estimates, including as a result of year-end closing procedures or review adjustments, and such changes could be material. These estimates should not be viewed as a substitute for full audited financial statements prepared in accordance with GAAP or as a measure of the Company’s performance.
About Heat Biologics, Inc. (NASDAQ:HTBX)
Heat Biologics, Inc. is a development-stage company focused on developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers. The Company is an immuno-oncology company, which focuses on T cell-stimulating platform technologies, such as Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combination Pan-Antigen Cytotoxic Therapy (ComPACT). Using its ImPACT platform technology, the Company has developed HS-410 (vesigenurtacel-L) as a product candidate to treat non-muscle invasive bladder cancer (NMIBC), and HS-110 (viagenpumatucel-L), which is intended for use in combination with an anti-PD-1 checkpoint inhibitor, as a potential treatment for patients with non-small cell lung cancer (NSCLC). Using its ComPACT platform technology, it has developed HS-120 as a potential treatment for NSCLC. It is conducting a Phase II trial of HS-410 in patients with NMIBC, and a Phase Ib trial of HS-110, in combination with nivolumab (Opdivo) to treat patients with NSCLC. Heat Biologics, Inc. (NASDAQ:HTBX) Recent Trading Information
Heat Biologics, Inc. (NASDAQ:HTBX) closed its last trading session 00.00 at 1.03 with 2,848,647 shares trading hands.